RIGL - Rigel Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

243.1M

Cash

49.55M

Avg Qtr Burn

-1.671M

Short % of Float

4.12%

Insider Ownership

2.19%

Institutional Own.

62.70%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
REZLIDHIA (Olutasidenib) (FT-2102) Details Cancer, Acute myeloid leukemia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
REZLIDHIA (Olutasidenib) (FT-2102) Details Glioma, Acute myeloid leukemia, Cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TAVALISSE® (fostamatinib disodium hexahydrate) Details Adult Chronic Immune Thrombocytopenia (ITP)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TAVALISSE® (fostamatinib disodium hexahydrate) Details COVID-19	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
REZLIDHIA (Olutasidenib) (FT-2102)+ temozolomide Details Glioma, Cancer	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
R552 Details Autoimmune disease, Rheumatoid arthritis	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
R289 Details Lower-risk myeloid dysplastic syndrome	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TAVALISSE® (fostamatinib disodium hexahydrate) Details Blood disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TAVALISSE® (fostamatinib disodium hexahydrate) Details COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.